


Viral Epidemiology Snapshot: December 15-21, 2024


Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

| <u>CoV-2, Flu, & RSV</u> | | | | | |
|------------------------------|----------------|------------------|-------------------|--|--|
| <u>Virus</u> | <u>#Tested</u> | <u>#Positive</u> | <u>% Positive</u> | | |
| Flu A | 896 | 120 | 13.4% | | |
| Flu B | 896 | 2 | 0.2% | | |
| RSV | 650 | 241 | 37.1% | | |
| CoV-2 | 738 | 43 | 5.8% | | |
| | | - · · | - | | |

| Bacterial Respiratory Infections (Molecular Tests) | | | | | |
|----------------------------------------------------|----------------|------------------|-------------------|--|--|
| <u>Organism</u> | <u>#Tested</u> | <u>#Positive</u> | <u>% Positive</u> | | |
| Bordetella parapertussis | 480 | 0 | 0.0% | | |
| Bordetella pertussis | 480 | 5 | 1.0% | | |
| Chlamydia pneumoniae | 467 | 0 | 0.0% | | |
| Mycoplasma pneumoniae | 473 | 17 | 3.6% | | |

| Other Respiratory Viruses | | | | | | |
|---------------------------|----------------|------------------|-------------------|--|--|--|
| <u>Virus</u> | <u>#Tested</u> | <u>#Positive</u> | <u>% Positive</u> | | | |
| Adenovirus | 467 | 23 | 4.9% | | | |
| Coronavirus 229E | 467 | 1 | 0.2% | | | |
| Coronavirus HKU1 | 467 | 0 | 0.0% | | | |
| Coronavirus NL63 | 467 | 23 | 4.9% | | | |
| Coronavirus OC43 | 467 | 5 | 1.1% | | | |
| Metapneumovirus | 467 | 9 | 1.9% | | | |
| Rhinovirus/Enterovirus | 467 | 137 | 29.3% | | | |
| Parainfluenza 1 | 467 | 3 | 0.6% | | | |
| Parainfluenza 2 | 467 | 1 | 0.2% | | | |
| Parainfluenza 3 | 467 | 5 | 1.1% | | | |
| Parainfluenza 4 | 467 | 12 | 2.6% | | | |





| Flu A Subtyping | | | | |
|-----------------|----|--|--|--|
| 2009 H1N1 | 2 | | | |
| Seasonal H1 | 0 | | | |
| Seasonal H3 | 24 | | | |
| No Subtype | 94 | | | |
| Pending subtype | 0 | | | |

This report contains results for all tests ordered throughout the CHMCA network. As of 9/19/23, the data set includes all Point of Care Testing performed at ACHPs and Urgent Care Centers, as well as the central hospital laboratories.

As of 10/1/23, SARS-CoV-2 will be tracked in total, rather than in "Diagnostic" and "Screening" categories

The top chart displays the 8-week trend for total number of positive tests for Flu A, Flu B, RSV, and SARS-CoV-2.

The bottom chart displays the 8week trend for positivity rate (# positive/ total # tested) Flu A, Flu B, RSV, and SARS-CoV-2.

